Skip to main content
. Author manuscript; available in PMC: 2024 Jun 1.
Published in final edited form as: Ann Allergy Asthma Immunol. 2023 Jan 24;130(6):699–712. doi: 10.1016/j.anai.2023.01.018

Figure 1.

Figure 1.

Secondary immune deficiencies following rituximab, such as hypogammaglobulinemia and late-onset neutropenia, subsequently lead to increased infection risk.